FDA warned LeanDreams over website claims that compounded semaglutide and tirzepatide match FDA-approved Ozempic, Wegovy, Mounjaro and Zepbound.
What happened
FDA reviewed LeanDreams' website in August 2025 and found it offered compounded semaglutide and tirzepatide. The site claimed the compounded semaglutide had the same active ingredient as Ozempic and Wegovy, and compounded tirzepatide had the same active ingredient as Mounjaro and Zepbound. FDA says these claims are false or misleading because compounded drugs are not FDA-approved.
What FDA found
The website claimed compounded semaglutide has the same active ingredient as Ozempic and Wegovy, which FDA says falsely implies it is the same as an FDA-approved drug.
FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The website claimed compounded tirzepatide has the same active ingredient as Mounjaro and Zepbound, which FDA says falsely implies it is the same as an FDA-approved drug.
FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]FDA says compounded drug products are not FDA-approved, so the website's comparisons are misleading and make the products misbranded.
FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The letter says introducing or delivering these misbranded drugs into interstate commerce is prohibited.
FDCA § 301(a) [21 U.S.C. § 331(a)]The letter also says receiving misbranded drugs in interstate commerce, or delivering them, is prohibited.
FDCA § 301(c) [21 U.S.C. § 331(c)]
What FDA wants
FDA tells LeanDreams to stop using the misleading claims immediately and to send a written response within 15 working days describing corrective steps and how it will prevent recurrence.
Who should pay attention
- telehealth weight-loss platforms selling compounded semaglutide or tirzepatide
- compounding pharmacies and marketers comparing products to FDA-approved brand drugs
- compliance teams reviewing drug promotional claims
This is a summary. Read the original letter on fda.gov.